Proton therapy developer Ion Beam Applications (IBA) and Azrieli Centre for Neuro-Radiochemistry at CAMH (Centre for Addiction and Mental Health) in Toronto have entered into a long-term agreement to promote nuclear medicine via R&D and a clinical program.
Together, IBA and CAMH will focus on discovering, developing, and testing new PET imaging agents for the early detection of diseases in fields such as neurology and oncology.
They entered into a formal agreement to increase collaboration, training, and effectiveness at the starting point of radiopharmaceutical discovery to the final stage of commercialization of promising candidates, according to IBA.
